

**REMARKS**

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

Applicants thank the Examiner for the telephone discussion held September 1, 2004 clarifying why the response filed May 26, 2004 was non-responsive to the Office Action of February 26, 2004. During this discussion, it was indicated that the amended claims are not as originally presented, because amended claims 17 and 22 omit the word "and" at line 3 between the terms "agonist activity" and "lauric diethanolamide." The Examiner suggested further amending claim 17 to recite "receptor agonist activity and lauric diethanolamide."

The present amendment hereby amends claims 17 and 22 as suggested by the Examiner. Support for this amendment can be found in original claims 17 and 22.

Therefore, in furtherance to the response filed May 26, 2004 and in view of the above amendment, the present application is in condition for allowance and early notice to that effect is hereby requested.

If it is determined that the application is not in condition for allowance, the Examiner is invited to telephone the undersigned attorney at the number below to expedite prosecution of the present application.

Respectfully submitted,

Yasuyuki SUZUKI et al.

By: Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/JFW/ksh  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 3, 2004